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Xeroderma pigmentosum (XP) is a rare recessive heredity disease caused by DNA
repair impairment characterized by photosensitivity and neurologic symptoms in half
of the cases. There are eight subtypes of XP: XP-A–XP-G and XP variant. Among
eight subtypes, XP complementation group A (XP-A) display the lowest DNA repair
ability and the severest cutaneous and neurologic symptoms. While its pathogenesis
of skin symptoms have been well-studied, that of neurological symptoms, including
sensorineural hearing loss (SNHL) remains unknown. Basic studies have suggested that
SNHL may be caused by inner ear damage, including damage to the spiral ganglion
neurons and organ of Corti, and that the XP-A is associated with most severe form
of SNHL in humans. Here, we report the occurrence of SNHL in Xpa-deficient mice.
Xpa-deficient mice and wild-type mice underwent measurements for auditory brainstem
response, and the results revealed that Xpa-deficient mice exhibited significantly greater
(p < 0.01) ABR thresholds at 4, 8, and 16 kHz than the wild-type mice. Furthermore, the
number of spiral ganglion neurons was reduced in Xpa-deficient mice compared with that
in wild-type mice, indicating that hearing loss may be related to spiral ganglion neuron
deficiency, consistent with the few reports published in human patients with XP. These
results provide important insights into the pathogenesis of SNHL in patients with XP-A.
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INTRODUCTION
Xeroderma pigmentosum (XP) is an autosomal recessive hereditary disease characterized by
increased susceptibility to freckle-like pigmentation and skin cancers at sun-exposed body sites
(DiGiovanna and Kraemer, 2012). Furthermore, some patients display neurological manifestations,
including hearing impairment. XP is classified into seven genetic complementation groups deficient
in nucleotide excision repair (A through G) and an XP-variant type; the relative frequency and
severity of cutaneous and neurological symptoms differ depending on the subtype. XP occurs at
a higher frequency in Japan (1:22,000; Hirai et al., 2006) than in the United States (1:250,000;
Robbins et al., 1974). Approximately 50% of all Japanese patients with XP are assigned to the
XP complementation group A (XP-A), and most patients with XP-A exhibit severe neurological
manifestations (Nishigori et al., 1994).
During daily life, humans are exposed to various genotoxic hazards; in order to protect the
body from these hazards, its constituent cells have multiple pathways for repair of DNA damage
caused by environmental agents, including endogenous factors such as reactive oxygen species
(ROS) and reactive nitrogen species (RNS), and exogenous factors such as UV radiation (UVR),
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ionizing radiation, electrophilic chemical adducts, and certain
drugs. If the DNA repair pathway fails to function properly,
replication, and transcription errors occur, resulting in cell death
and mutation. The occurrence of mutations leads to failure
of normal metabolism, resulting in aging and carcinogenesis
(Menck and Munford, 2014). One of the major DNA repair
pathways is nucleotide excision repair (NER), in which XPA–
XPG proteins function in a complementary manner (Naegeli
and Sugasawa, 2011). However, patients with XP lack one of
the NER protein complexes, and therefore show an impaired
capacity to properly repair DNA lesions that cause structural
distortion, such as dipyrimidine photoproducts, which is caused
by ultraviolet radiation (UVR), as well as DNA adducts caused
by drugs (Cleaver, 2005). In addition, several studies have shown
that NER plays a partial role in repair of damage caused by ROS
produced during endogenous metabolism (Menck andMunford,
2014).
The skin and mucosal symptoms in patients with XP
are attributed to deficiencies in the repair of UVR-induced
DNA damage. Patients with XP-A suffer severe sunburn upon
minimum sun exposure and gradually develop many freckle-
like pigmentated maculae. These individuals also develop skin
cancers such as basal cell carcinoma, squamous cell carcinoma,
and malignant melanoma, in addition to actinic keratosis, which
is a precancerous lesion. Unless photoprotection is adhered
to, most patients with XP-A develop skin cancer before the
age of 10. Moreover, most patients with XP-A also exhibit
progressive degenerative neurological manifestations, including
mental deterioration, microcephaly, sensorineural hearing loss
(SNHL), abnormal speech, areflexia, and peripheral neuropathy
(Nishigori et al., 1994; Bradford et al., 2011). Hearing loss in XP-A
patients may appear from the age of about 6 years and up through
their 20s, eventually becoming severe in their late 30s–40s
(Nishigori et al., 1994; Totonchy et al., 2013). The representative
manifestation of hearing impairment in patients with XP-A
harboring a homozygous IVS3-1G>Cmissplice mutation ofXPA
is bilateral severe to profound hearing loss; the audiogram is
usually horizontal or worse at higher frequencies.
However, the mechanisms mediating these neurological
symptoms in patients with XP-A remain unclear because UVR
cannot penetrate through the skin layers to reach the nervous
system. Some studies have shown that generation of ROS results
in neuronal cell death in patients with XP (Anttinen et al., 2008;
Viana et al., 2013). Additionally, researchers have outlined two
major hypotheses to explain the pathogenesis of neurological
degeneration in XP: (1) there is a deficiency in the ability to repair
cyclo-purine, which is induced by oxidative stress through daily
aerobic metabolism; or (2) cells cannot effectively repair some
types of ROS generated during normal metabolism. However, the
specific mechanisms remain unknown.
Among the neurological symptoms observed in patients with
XP-A, hearing impairment has been shown to develop at a
relatively young age (Nishigori et al., 1994). However, because XP
is a very rare disorder, few studies have examined the progression
of SNHL. Therefore, the present study was conducted to
characterize the mechanisms of neurological dysfunction and
hearing impairment in patients with XP through evaluation
of hearing loss in Xpa-deficient mice and the mechanisms
involved.
MATERIALS AND METHODS
Animals
Xpa-deficient mice with CBA (15), C57BL/6, and CD-1 chimeric
backgrounds, which were first generated by insertion of
neomycin cassette sequences into exon 4 of the Xpa gene using
embryonic stem (ES) cell techniques (Nakane et al., 1995), were
backcrossed with hairless albino mice from the Balb/cA Kud-
hr inbred strain (Itoh et al., 2005). The resulting hairless albino
Xpa (+/–) mice were kindly provided by Professor Kiyoji Tanaka
(Nakane et al., 1995). We repeatedly mated these mice, and the
resulting hairless albino Xpa (+/+) mice were used as wild-
type (WT) mice whereas hairless-albino-Xpa (–/–) mice were
used as Xpa-deficient mice. Mice aged 38–40 weeks were used
in this study. Six Xpa-deficient mice were used for evaluation
of hearing level, spiral ganglion neuron (SGN) count, stria
vascularis thickness, and hair cell count, and five WT mice
served as the control group. Mice were housed under specific
pathogen-free conditions with a 12-h light/dark cycle (lights on
at 6:00 A.M.; lights off at 6:00 P.M.). All animal procedures were
approved by the Institutional Review Board of Kobe University
Graduate School of Medicine (Permit Number: P140613), and
animal experiments were conducted according to the Guidelines
of the Institutional Animal Care and Use Committee of Kobe
University Graduate School of Medicine. All attempts were made
to minimize animal use and suffering.
Evaluation of Hearing Function by Auditory
Brainstem Response (ABR)
Mouse hearing function was determined in six Xpa-deficient
and five WT mice by measuring the ABR at 38–40 weeks of
age, as previously described (Fujita et al., 2015). Prior to the
measurements, the mice were anesthetized by intraperitoneal
injection of midazolam (10 mg/kg), medetomidine (37.5µg/kg),
and butorphanol tartrate (0.5 mg/kg). ABR was measured
using waveform storing and stimulus control with Scope
software incorporated in a PowerLab system (PowerLab2/26; AD
Instruments, Castle Hill, Australia), and electroencephalogram
(EEG) recording was performed with an extracellular amplifier
AC PreAmplifier (P-55; Astro-Med, West Warwick, RI, USA).
Sound stimuli were produced by a coupler-type speaker (ES1spc;
Bio Research Center, Nagoya, Japan) inserted into the external
auditory canal of mice. Tone burst stimuli, with a 0.2-ms rise/fall
time (cosine gate) and 1-ms flat segment at frequencies of 4,
8, and 16 kHz were generated, and the amplitude was specified
using a sound generator and an attenuation real-time processor
and programmable attenuator (RP2.1 and PA5; Tucker-Davis
Technologies, FL). Sound-level calibrations were performed
using a sound level meter (NA-42; Rion, Tokyo, Japan). For
recording, stainless steel needle electrodes were placed at the
vertex and ventrolateral to the left and right ears. Generally, ABR
waveforms were recorded for 12.8 ms at a sampling rate of 40,000
Hz using 50–5000 Hz band-pass filter settings; waveforms from
256 stimuli at a frequency of 9 Hz were averaged. In each animal,
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ABR was measured in both ears. ABR waveforms were recorded
at sound pressure level (SPL) intervals of 5 dB down from the
maximum amplitude until no waveform could be visualized.
The lowest sound pressure level for which the last waveform
was detected was recorded as the animal’s hearing level. If a
strong waveform suddenly disappeared when the sound level was
lowered by 5 dB, we considered the hearing level to be the interval
between the sound pressure levels. The largest wavelet was used
for determination of ABR threshold.
Morphological Evaluation of Cochleae
After ABR measurements, the mice were sacrificed by deep
anesthesia and cervical dislocation, and cochleae were removed.
Removed cochleae were then fixed in 4% paraformaldehyde
overnight, incubated in 10% ethylenediaminetetraacetic acid
disodium salt dehydrate (pH 7.0, Muto Pure Chemicals, Tokyo,
Japan) at room temperature for 2 days. Cochleae were dehydrated
through a graded ethanol series and xylene, embedded in paraffin,
and then sectioned at 3.0µm in the midmodiolar plane.
Cochlear tissue sections on slides were stained with
hematoxylin (Muto Pure Chemicals, Tokyo, Japan) and
eosin (Wako Pure Chemicals Industries, Osaka, Japan), referred
to as H-E staining, for histopathological evaluations. Cochlear
specimens were observed using a light microscope system
(BZ-9000; Keyence, Osaka, Japan) and the digital images were
saved.
Spiral Ganglion Neuron (SGN) Count
SGNs were counted using six Xpa-deficient and five WT mice.
Three midmodiolar sections (30 µm apart) were selected from
each cochlea. The area of Rosenthal’s canal and the cochlear turns
were quantified by measuring their cut surfaces using BZ-H1AE
microscope analysis software (Keyence, Osaka, Japan). All SGNs
within each measured area were counted for each cochlear turn
(apical, middle, basal). The SGN cell density was determined as
the average number of nuclei per 10,000µm2 of Rosenthal’s canal
for three sections in each cochlear turn, as described previously
(Fujita et al., 2012).
Measurement of Stria Vascularis Thickness
Stria vascularis thickness was measured using six Xpa-deficient
and five WT mice. The slides were evaluated from ×40 images.
The thickness was defined as the distance between the margin of
the stria and the junction of the basal cells with the spiral ligament
halfway between the attachment of Reissner’s membrane and the
spiral prominence (Han et al., 2016a). Six to seven sections of the
apical, middle, and basal regions of the cochlea for each mouse
and the averages for each region were calculated.
Hair Cell Count
Hair cells were counted using six Xpa-deficient and five WT
mice. Outer hair cells (OHCs) and inner hair cells (IHCs) were
counted in ×40 images of the apical, middle, and basal cochlear
regions. Six to thirteen sections of each turn were evaluated in
one cochlea per mouse. Hair cells were identified by the presence
of a nucleus. Percentage of OHC survival was calculated as the
number of intact OHCs present among the three OHCs that
should be observed in cochlear sections of mice with normal
hearing. Percentage of IHC survival was calculated as the number
of intact IHCs present among the one IHC that should be
observed in cochlear sections of mice with normal hearing (Han
et al., 2016b).
Data Analysis
All data are reported as the mean ± standard error (SE). The
ABR threshold levels, SGN density, stria vascularis thickness,
and hair cell percentage were assessed by non-paired t-tests
(R software ver. 3.0.2; R Foundation for Statistical Computing,
2013). Differences with p-values of <0.01 were considered
significant.
RESULTS
ABR Thresholds in Xpa-Deficient Mice And
WT Mice
Our preliminary data suggested that Xpa-deficient mice had
almost the same ABR thresholds as WT mice at 20 weeks of age
(20–40 dB). At 60 weeks of age, the ABR thresholds of both Xpa-
deficient and WT mice had nearly reached the upper limit of
detection (i.e., for this ABR technique, 85 dB SPL at 4 kHz, 80
dB SPL at 8 kHz, and 80 dB SPL at 16 kHz; data not shown).
Therefore, we used mice at 38–40 weeks of age in order to detect
differences in ABR thresholds between the two genotypes.
Interestingly, Xpa-deficient mice exhibited significantly
higher threshold elevation than WT mice at all ABR frequencies
(4, 8, and 16 kHz; Figure 1A). The average threshold levels
(±SE) in Xpa-deficient mice were 79.5 ± 1.7, 71.9 ± 3.4, and 67
± 3.4 dB SPL at 4, 8, and 16 kHz, respectively, whereas those
in WT mice were 50 ± 3.8, 31.9 ± 4.6, and 27.7 ± 3.7 dB SPL,
respectively. Figure 1B shows the ABR waveforms of WT and
Xpa-deficient mice.
Morphological Evaluation of the Cochlea
Figure 2 show representative H-E sections of the cochlear middle
turn in WT mice (A) and Xpa-deficient mice (B). There were no
obvious inter-group differences in the stria vascularis or organ of
Corti. However, the SGN showed lower density in Xpa-deficient
mice than in WT mice.
SGN Count
In Xpa-deficient mice, the SGN count was lower in all regions of
the cochlea relative toWTmice. The average SGN count (±SE) in
Xpa-deficient mice andWTmice was 12.6± 1.1/10,000 and 19±
1.3/10,000µm2, respectively, in the apical turn; 12.7± 1.0/10,000
and 21.3± 0.8/10,000 µm2, respectively, in the middle turn; and
5.4 ± 0.7/10,000 and 7.9 ± 0.7/10,000 µm2, respectively, in the
basal turn (Figure 3). The SGN count was significantly lower in
Xpa-deficient mice than in WT mice in the apical and middle
turns (p < 0.01).
Measurement of Stria Vascularis Thickness
There was no significant difference in stria vascularis thickness
between Xpa-deficient mice and WT mice (p > 0.01). The
average thickness (±SE) of the stria vascularis in WT mice and
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FIGURE 1 | (A) ABR threshold level in WT mice and Xpa-deficient mice at frequencies of 4, 8, and 16 kHz. Data are means ± SE. *P < 0.01 for comparisons
between WT mice and Xpa-deficient mice. (B) Representative ABR waveforms at 4000 Hz in WT mice and Xpa-deficient mice. ABR threshould of the
Xpa-deficient mice was determined as 85 dB SPL.
FIGURE 2 | Histopathology of the cochlear tissue of WT mice (A) and Xpa-deficient mice (B). H-E staining; (scale bar = 50 µm). Cross-section through the
middle turn of the cochlea parallel to the modiolus, organ of Corti (OC), stria vascularis, and spiral ganglion neurons (SGNs) in the middle turn of the cochlea.
Xpa-deficient mice group was 13.0 ± 0.5 and 13.8 ± 1.1 µm,
respectively, in the apical turn; 16.5 ± 2.0 and 14.9 ± 1.0 µm,
respectively, in the middle turn; and 17.7 ± 0.9 and 17.9 ± 0.9
µm, respectively, in the basal turn (Figure 4).
Hair Cell Count
There was no significant difference in the percentages of OHC
and IHC remaining between Xpa-deficient mice andWTmice (p
> 0.01). The average OHC percentage (±SE) in WT mice and
Xpa-deficient mice was 71.7 ± 5.6 and 60.5 ± 9.5%, respectively,
in the apical turn; 67.0± 4.6 and 54.4± 7.7%, respectively, in the
middle turn; and 45.7± 5.3 and 37.4± 5.9%, respectively, in the
basal turn. The average IHC percentage (±SE) in WT mice and
Xpa-deficient mice was 69.5± 5.6 and 63.1± 13.0%, respectively,
in the apical turn; 70.8± 3.9 and 53.1± 4.8%, respectively, in the
middle turn; and 26.5 ± 8.5 and 19.4± 9.0%, respectively, in the
basal turn (Figure 5).
DISCUSSION
In this study of hearing loss in Xpa-deficient mice, we found
that these mice exhibited SNHL, with significantly higher hearing
thresholds at frequencies of 4, 8, and 16 kHz, relative to those
in WT mice. We also observed lower numbers of SGNs in
these mice, providing important insights into the pathogenesis
of SNHL in patients with XP-A. Unlike patients with XP-A,
however, no other features suggestive of neurologic symptoms
other than SNHL were evident in Xpa-deficient mice.
Very few studies have described the audiological
characteristics of SNHL and otopathology in patients with
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FIGURE 3 | Mean densities of spiral ganglion neurons in WT mice and Xpa-deficient mice. Data represent mean ± SE. *P < 0.01 for comparisons between
WT mice and Xpa-deficient mice. N.S., no significant difference between WT mice and Xpa-deficient mice.
FIGURE 4 | Mean thickness of the stria vascularis (SV) in WT mice and Xpa-deficient mice. Data represent mean ± SE. N.S., no significant difference
between WT mice and Xpa-deficient mice.
XP. Kenyon et al. (1985) reported three XP patients who had
impaired hearing and concluded that the hearing loss had a
cochlear origin based on data for brainstem evoked potentials
and electrocochleography (Kenyon et al., 1985). Additionally,
Totonchy et al. (2013) found that 44 and 53% of patients with
XP-A and XP-D, respectively, had hearing loss. Moreover,
patients who exhibited hearing loss also tended to have other
neurological manifestations (Totonchy et al., 2013). Similarly,
Nishigori et al. (1994) reported that 15 of 29 patients with
XP-A exhibited hearing impairment, most also having other
neurological abnormalities such as peripheral nerve dysfunction,
ataxia, mental retardation, and brain atrophy (Nishigori
et al., 1994). It is known that there is a genotype-phenotype
correlation in XP-A (Nishigori et al., 1994) and that more
than 85% of Japanese patients with XP-A harbor a IVS-1G>C
mutation, which results in absence of the XPA protein due
to aberrant splicing, creating the severest clinical symptoms
among XP-A patients. XP-A patients harboring IVS-1G>C begin
to manifest neurologic abnormalities such as ataxia, hearing
impairment, and neuroimaging abnormalities around 6 years
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FIGURE 5 | Mean percentage of outer hair (OH) cells and inner hair (IH) cells remaining in WT mice and Xpa-deficient mice. Data are means ± SE. N.S.,
no significant difference between WT mice and Xpa-deficient mice.
of age (Nishigori et al., 1994; Ueda et al., 2012). It has also
been reported that XP-A patients begin to manifest hearing
impairment in their 20s, and that the condition becomes severe
by their late 30s (Totonchy et al., 2013). This is in accord
with our preliminary finding that the difference between the
two mouse genotypes became apparent around 40 weeks of
age, and is consistent with the notion that the neurologic
symptoms of XP represent a progressive neurodegenerative
disorder.
Few previous human studies have described the areas
of the otological system responsible for hearing loss. In a
recent autopsy study, researchers analyzed the temporal bone
histopathology in a 44 year-old patient with XP-A who had
suffered bilateral progressive SNHL that began during her second
decade of life. Diffuse and severe atrophy of the organ of
Corti and SGNs was evident. However, in the apical half of
the cochlea, hair cells remained, despite severe degeneration
of the SGNs, suggesting that the hearing loss had been
partly due to neural degeneration (Totonchy et al., 2013;
Viana et al., 2013). In another patient with XP who had
had mild hearing loss and died of cancer at the age of 49
years, there were no abnormalities in the inner ear; however,
the dorsal root ganglia showed neuronal loss. The author
concluded that primary neuronal degeneration began initially
in the peripheral nervous system (Robbins et al., 2002). In our
present study of Xpa-deficient mice, SGNs were severely atrophic
in comparison with those in age-matched controls, whereas
there were no differences in stria vascularis thickness and the
percentage of remaining hair cells betweenXpa-deficient andWT
mice.
The gene products responsible for each XP-complementation
group are involved in each step of NER, including DNA
damage recognition, DNA double-strand unwinding, excision
of the damaged DNA with some flanking oligonucleotides,
repair synthesis along with the daughter strand, and ligation
of the newly synthesized fragment (Fousteri and Mullenders,
2008). Including XPA, the NER proteins exist in the cochleae
of albino Fischer344 rats, and the NER pathway is involved in
the repair of DNA damage caused by cisplatin. Additionally,
cytoplasmic-to-nuclear translocation of XPA protein has been
detected within SGNs during cycles of cisplatin treatment
(Guthrie et al., 2008), indicating that XPA protein recognizes
the DNA damage resulting from exogenous and/or endogenous
hazards, and this is considered to be the main function of
XPA protein in SGNs. Indeed, the effects of oxidative stress
and the antioxidant system on the aging cochlea and central
nervous system have been well-characterized. ROS, a natural
byproduct of aerobic metabolism, causes chronic damage to
ear structures (Staecker et al., 2001). Moreover, Brooks has
reported that 8,5′-cyclopurine-2′-deoxynucleosides, which are
induced by oxidative stress, may represent a candidate for
production of the neurodegenerative DNA lesions in patients
with XP (Brooks, 2008). We hypothesize that ROS generated
during normal metabolismmay cause SGN death in patients with
XP-A.
Although our data do not fully demonstrate that hearing
deficiency in patients with XP-A is caused by disruption
of spiral neurons, it will be essential to examine cochlear
morphology in younger mice, including immunostaining for
detection of apoptosis in cochlear sections. Moreover, it may
be informative to examine various brain regions in Xpa-
deficient mice. Elucidation of the specific mechanisms leading
to hearing loss in these mice may provide important insights
into XP-A in humans and facilitate our understanding of other
neurological deficiencies in patients with XP. This model system
could be useful for assessing methods to preserve hearing
in XP-A patients, and might provide a tool for screening of
therapeutic drugs for XP-A in future. Furthermore, it might also
provide insights into mechanisms of hearing loss in the general
population.
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CONCLUSION
Xpa-deficient mice tend to exhibit SNHL at an earlier age than
WT mice, and morphological analyses of the cochlea in Xpa-
deficient mice suggest degeneration of SGNs.
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